Loading clinical trials...
Loading clinical trials...
Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts
The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction
Age
18 - 90 years
Sex
ALL
Healthy Volunteers
No
Graz, Styria, Austria
Graz, Styria, Austria
Linz, Upper Austria, Austria
Vienna, Vienna, Austria
Salzburg, Austria
Prague, Czechia
Cologne, North Rhine-Westphalia, Germany
Start Date
July 1, 2010
Primary Completion Date
October 1, 2012
Completion Date
October 1, 2012
Last Updated
November 4, 2014
39
ACTUAL participants
Riociguat (BAY63-2521)
DRUG
Riociguat (BAY63-2521)
DRUG
Riociguat (BAY63-2521)
DRUG
Placebo
DRUG
Lead Sponsor
Bayer
NCT07079592
NCT05719415
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions